Skip to search formSkip to main contentSkip to account menu

LY2963016 insulin glargine

Known as: LY IGlar 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Insulin Glargine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a…
Abstract Objective: We compared the clinical course of type 2 diabetic patients whose basal insulin preparations were replaced… 
2018
2018
Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi ( LixiLan ) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2…
2017
2017
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union
2017
2017
Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
To re‐analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V, in which the once… 
2017
2017
Étude DUAL V : l’efficacité d’IDegLira est indépendante de la dose d’insuline glargine administrée avant l’étude
2017
2017
Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline…
2016
2016
The in vitro pharmacology of LY IGlar (LY2963016): A new insulin glargine product
Objective: Basal insulin analogs, with durations of action sufficient for coverage over the course of 24h, are important for the… 
2016
2016
CA-019: Pharmacologie in vitro de LY IGlar (LY2963016, Insulin Glargine)
2013
2013
O12 L’insuline Dégludec (IDeg) réduit systématiquement le taux d’hypoglycémies nocturnes tout en diminuant la glycémie à jeun (GAJ), comparée à l’insuline Glargine (IGlar) : Analyse de 7 essais…
2012
2012
O37 L’insuline dégludec comparée à l’insuline glargine diminue le nombre d’épisodes d’hypoglycémie nocturne: résultats à 1 an des essais randomisés en basal-bolus chez des diabétiques de type 1 (DT1…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)